Definium Therapeutics (DFTX) vs Philip Morris International (PM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Definium Therapeutics (DFTX) has outperformed Philip Morris International (PM) over the past year, gaining 193.1% versus a gain of 24.7%. Over five years, PM leads with a +95.9% price change compared with -0.5% for DFTX. Philip Morris International is the larger company by market cap ($300.33 billion vs $4.71 billion), about 63.7 times the size.
Philip Morris International pays a dividend yielding 3.05%, while Definium Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DFTX | PM |
|---|---|---|
| Share price | $35.09 | $192.69 |
| Market cap | $4.71B | $300.33B |
| 1-day change | -1.49% | +1.20% |
| YTD return | +162.06% | +20.13% |
| 1-year return | +193.15% | +24.68% |
| 5-year return | -0.45% | +95.88% |
| P/E ratio (TTM) | — | 27.69 |
| Forward P/E | — | 20.98 |
| EPS (TTM) | $-3.43 | $6.96 |
| Dividend yield | 0.00% | 3.05% |
| Annual dividend | $0.00 | $5.88 |
| Revenue (latest FY) | — | $40.65B |
| Revenue growth (YoY) | — | +7.31% |
| Net income (latest FY) | $-183.79M | $11.35B |
| Gross margin | — | 67.12% |
| Operating margin | — | 36.64% |
| Net margin | — | 27.92% |
| 52-week high | $49.70 | $207.76 |
| 52-week low | $10.47 | $142.11 |
| Distance from 52-week high | -29.40% | -7.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +104.19% | +8.01% |
| Average volume | 2.15M | 4.65M |
| Shares outstanding | 134.37M | 1.56B |
| Employees | 105 | 84,900 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Philip Morris International is about 63.7 times larger than Definium Therapeutics by market value ($300.33B vs $4.71B).
- DFTX has outperformed PM by 168.5 percentage points over the past year.
- Philip Morris International offers a meaningfully higher dividend yield (3.05% vs 0.00%).
About Definium Therapeutics
DFTX stock →Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 105 employees
About Philip Morris International
PM stock →Philip Morris International Inc. operates as a tobacco company.
Health Care · Medicinal Chemicals and Botanical Products · 84,900 employees
DFTX vs PM FAQ
Which is bigger, Definium Therapeutics or Philip Morris International?
Philip Morris International (PM) is larger, with a market capitalization of $300.33B compared with $4.71B for Definium Therapeutics (DFTX).
Which stock has performed better over the past year, DFTX or PM?
DFTX returned +193.15% over the past 12 months, compared with +24.68% for PM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Definium Therapeutics or Philip Morris International?
Philip Morris International pays a dividend yielding 3.05%, while Definium Therapeutics does not currently pay a regular dividend.
Are Definium Therapeutics and Philip Morris International in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.